High-Protein Diet to Protect Muscle in Adults with Obesity on GLP-1 Medicines
Tests extra dietary protein to preserve muscle in adults with obesity taking GLP-1 medicines.
Plain-language title generated from the registry record
Registry title: Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance
Key facts
- Where
- Heraklion, GreeceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT07495904, who can take part
Where in Greece
- 1st Department of Internal Medicine, University General Hospital of HeraklionHeraklion, GreeceTaking people
- Human Dietetics & Body Composition Laboratory, Department of Nutrition and Dietetics Sciences, Hellenic Mediterranean UniversityHeraklion, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hellenic Mediterranean University
- Trial code
- NCT07495904
- Record updated
- 2 April 2026
- Original description
This study investigates how weight-loss medications, specifically GLP-1 receptor agonists, affect body composition, with a special focus on preserving muscle mass in adults with obesity. While these medications are highly effective for weight loss, they can sometimes lead to an unwanted loss of valuable muscle mass (a condition that can lead to sarcopenia).Read full original descriptionShow less
The Effect of GLP-1 Receptor Agonist-based Treatment on Body Composition and Muscle Mass in Adults With Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance
This study investigates how weight-loss medications, specifically GLP-1 receptor agonists, affect body composition, with a special focus on preserving muscle mass in adults with obesity. While these medications are highly effective for weight loss, they can sometimes lead to an unwanted loss of valuable muscle mass (a condition that can lead to sarcopenia).
To explore how to prevent this, researchers are conducting a 3- to 6-month randomized controlled trial involving adults aged 30 to 65 years with a BMI greater than 30 kg/m². Participants who are receiving GLP-1 medications will be randomly assigned to one of two groups: one group will receive the standard medication treatment alone, while the other group will receive the medication along with specific dietary guidance focused on increasing daily protein intake.
Inclusion: Adults 30-65 years old; BMI: ≥30 kg/m²; Signed Informed Consent.
Exclusion: Chronic use of medications affecting metabolism or body composition (e.g., corticosteroids, anti-obesity drugs); Use of anti-inflammatory or antioxidant medications; Unstable medication regimen (changes within the past 3 months); Metabolic and Medical Conditions:; Known cardiovascular disease (e.g., coronary artery disease, heart failure NYHA 3-4); Inflammatory bowel disease; Celiac disease; History of pancreatitis; Any disorder potentially causing malabsorption; Active cancer or history of malignancy within the past 3 years; Psychiatric disorders affecting adherence or assessment B. Medication and Supplement Use; Any condition that, in the opinion of the Investigator, may interfere with participation, adherence, or the interpretation of study results; Uncontrolled type 2 diabetes (HbA1c > 9.0%); Chronic kidney disease stage 4-5 (GFR <60 ml/min); Liver disease (known hepatitis, ALT ≥ 3 or total bilirubin ≥ 2 times ULN); Use of probiotics, prebiotics, or laxatives within the last month; Use of protein and creatine supplements; Dietary and Lifestyle Factors:; Alcohol or substance abuse; Engagement in intense regular physical activity; Reproductive Status:; Pregnancy or breastfeeding; Pregnancy within the past 12 months; Plans to become pregnant during the study; Other:.